Brain tumor magnetic resonance spectroscopy NCD
This article was originally published in The Gray Sheet
Executive Summary
Decision date is delayed until Nov. 28 to "permit additional review and clearances," CMS announces Oct. 30. An AHRQ tech assessment found that limited availability of the indicated condition has made it difficult to undertake the clinical trials required for national coverage (1"The Gray Sheet" June 23, 2003, p. 24)...
You may also be interested in...
AHRQ Brain Tumor MRS Tech Assessment Makes NCD Reversal Doubtful
The limited availability of magnetic resonance spectroscopy (MRS) for diagnosing brain tumors has made it difficult to pursue the types of large clinical trials necessary for obtaining national coverage, according to an 1AHRQ tech assessment
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.
Partisan Politics Returns To US FDA Congressional Oversight
The US FDA has stood out as an agency that tends to draw broad bipartisan support amid a generally rancorous and divided Congress. A House hearing, however, may be a sign that those days are over.